Breast Cancer
Conditions
Keywords
Breast cancer, Neoadjuvant chemotherapy, EndoTAG-1
Brief summary
The study hypothesis is that the new drug EndoTAG-1 will improve tumor volume reduction as measured by Magnetic Resonance Imaging when added to a standard chemotherapy regimen of weekly paclitaxel. This is a prospective single-center study that will investigate the activity of EndoTAG-1 + paclitaxel combination therapy in patients with HER2-negative breast cancer that are candidate for receiving chemotherapy before surgery (neoadjuvant chemotherapy).
Detailed description
This is a prospective, single-center, open-label phase II clinical trial investigating the activity of EndoTAG-1 + paclitaxel combination therapy in patients with HER2-negative BC candidate for neoadjuvant chemotherapy, as measured by the decrease in MRI-estimated tumour volume at the end of EndoTAG-1 + paclitaxel administration. Patients will be stratified by hormone receptor status. A total of 20 female patients with non-metastatic HER2-negative breast cancer candidate for neoadjuvant chemotherapy and meeting all study eligibility criteria will receive 12 weekly infusions of EndoTAG-1 (22 mg/m2 liposomal paclitaxel) in combination with paclitaxel (70 mg/m2) followed by 3 cycles of FEC (Fluorouracil 500mg/m2, Epirubicin 100mg/m2, Cyclophosphamide 500mg/m2) every 3 weeks (experimental group) The study hypothesis is that EndoTAG-1 will improve MRI- estimated volume reduction when added to weekly paclitaxel. The null hypothesis is that combination has no or a negligible effect on volume reduction (defined as lower or equal to a 50% decrease) versus the alternative hypothesis that the combination yields at least a 80% average decrease in MRI- estimated volume at the end of weekly paclitaxel and EndoTAG-1 administration from baseline
Interventions
DRUGEndoTAG-1
EndoTAG-1 (22 mg/m2 liposomal paclitaxel) + Paclitaxel (70 mg/m2) Weekly i.v. infusions of EndoTAG-1 and paclitaxel for 12 weeks followed by subsequent treatment with the standard FEC regimen (Fluorouracil 500 mg/m2, Epirubicin 100 mg/m2, Cyclophosphamide 500 mg/m2) once every 3 weeks for 3 cycles of therapy followed by surgery.
Sponsors
Jules Bordet Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. newly diagnosed histologically confirmed BC with breast infiltrating carcinoma of histological grade \> 1 (either operable, or locally advanced or inflammatory) candidate for neoadjuvant chemotherapy 2. HER2-negative tumor, defined according to immunohistochemistry or using fluorescent in-situ hybridization (FISH) 3. ECOG performance status 0 or 1 4. Gender: female 5. Age : \>= 18 years old 6. Negative pregnancy test (females of childbearing potential) 7. Willingness to perform double-barrier-contraception during study and for 6 months post chemotherapy treatment (females of childbearing potential) 8. Signed informed consent
Exclusion criteria
1. Metastatic or relapsed disease 2. Major surgery \< 3 weeks prior to enrollment 3. Severe pulmonary obstructive or restrictive disease 4. Uncontrolled inflammatory disease (autoimmune or infectious) 5. Clinically significant cardiac disease (NYHA stadium \> 2) 6. Results of laboratory tests (hematology, chemistry) outside specified limits: * WBC ≤ 3 x 109/L * ANC \< 1.5 x 109/L * Platelets \< 100 x 109/L * Hb ≤ 9.0 g/dl (≤ 5.6 mmol/l) * PTT/ INR \> 1.5 x ULN * AST or ALT \> 2.5 x ULN * Alkaline Phosphatase \> 2 x ULN * Total Bilirubin \> 1.5 x ULN 7. Pregnancy or nursing status 8. Known positive HIV testing 9. Known hypersensitivity to any component of the EndoTAG-1, paclitaxel or FEC formulations 10. History of malignancy other than breast cancer \< 5 years prior to enrollment, except skin cancer (i.e. basal or squamous cell carcinoma) treated locally 11. History of active or significant neurological disorder or psychiatric disorder that would prohibit the understanding and giving of informed consent, or would interfere in the clinical and radiological evaluation of central nervous system during the trial 12. Concurrent treatment with other experimental products. Participation in another clinical trial with any investigational product within 30 days prior to study entry
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| MRI-estimated tumour volume at the end of neoadjuvant EndoTAG-1 + paclitaxel administration vs. baseline. | 15 weeks after start of neoadjuvant chemotherapy. | To investigate the activity of EndoTAG-1 + paclitaxel combination therapy in patients with HER2-negative BC candidate for neoadjuvant chemotherapy, as measured by the decrease in MRI-estimated tumour volume at the end of neoadjuvant EndoTAG-1 + paclitaxel administration vs. baseline. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rate of pathological complete response (pCR). | 27 weeks after start of neoadjuvant chemotherapy. | Rate of pathological complete response (pCR) at the end of neo-adjuvant chemotherapy. |
Countries
Belgium
Outcome results
None listed